JAGX
Jaguar Health, Inc.
$2.31
-0.06 (-2.53%)
At close · Jul 10
Going-concern doubt
— flagged May 20, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions, along with recurring operating losses and an accumulated deficit, raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these consolidated financial statements.”View the 10-Q filed May 20, 2026
Market Cap
$1.39M
Shares
603,134
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.31
Open$2.35
Day$2.21–2.35
52W$2.12–97.65
Avg vol 30d77K
Short int74K · 12.2% float · 1.0d
Short vol20%
Last earningsMay 20, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 20
Up next
Next earnings call
Aug 20, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 20, 2026
Equibles Rating
blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−92%
below
Price vs 50-day avg
−28%
below
RSI (14)
32
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−16%
trailing
6-month return
−91%
trailing
YTD return
−93%
this year
Relative strength
−100%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $30 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.24% of float · ▲ +34.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
11 holders — near 1-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
−2%
Y/Y
EPS growth
+82%
Y/Y
Free cash flow
$-23.7M
Balance sheet
$5.0M
net debt
Quant / Vol
risk profile
Volatility
154%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
14.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−92%
Bearish
Price vs 50-day avg
−28%
Bearish
RSI (14)
32
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $30 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.24% of float · ▲ +34.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
11 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $2 · 0%
52-wk high $98
vs 200-day avg -92%
vs 50-day avg -28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP EBITDA non-GAAP | -$5,688K | Three Months Ending March 31, 2026 | — |
| Non-GAAP Recurring EBITDA non-GAAP | -$5,060K | Three Months Ending March 31, 2026 | — |
|
|
|||
| Mytesi Prescription Volume | 5.8% | the fourth quarter of 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JAGX
this stock
Jaguar Health, Inc.
|
$1.39M | -92.9% | +19.8% | — | 12.2% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +9.5% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
11
- % held
- 42.6%
- Net QoQ
- +191.3K sh
- Top holder
- UBS Group AG
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JAGX | -17.8% | -16.0% | -91.4% | -23.0% | -92.9% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -19.2% | -20.1% | -100.4% | -24.1% | -103.6% |